A Phase 4 interventional study of metformin in Dyslipidemia, sponsored by Central South University. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-01-29.
Sponsored by Central South University · Phase 4, Interventional, and Treatment
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Metformin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic-induced dyslipidemia.
The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention.162 patients were randomized to one of two 24-week individual treatments: metformin (1000mg/day)or placebo. Medications were provided in double-blind fashion.The assessments include lipid levels, body weight, body mass index, fasting glucose, fasting insulin and insulin resistance index.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 162 is above the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Central South University is the lead sponsor of 126 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.
-
Exclusion Criteria:
liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus
metformin
Drug: metformin
placebo
1000mg/day for 24 weeks
low-density lipoprotein cholesterol
Time frame: 8 weeks
high-density lipoprotein cholesterol
Time frame: 8 weeks
adverse effects
Time frame: 8 weeks
body mass index
Time frame: 8 weeks
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central South University